These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9969455)

  • 1. Alpha decay of 231U to levels in 227Th.
    Liang CF; Sheline RK; Paris P; Hussonois M; Ledu JF; Isabelle DB
    Phys Rev C Nucl Phys; 1994 Apr; 49(4):2230-2232. PubMed ID: 9969455
    [No Abstract]   [Full Text] [Related]  

  • 2. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
    Dahle J; Bruland OS; Larsen RH
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):186-92. PubMed ID: 18722269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteosarcoma risk after simultaneous incorporation of the long-lived radionuclide 227Ac and the short-lived radionuclide 227Th.
    Müller WA; Murray AB; Linzner U; Luz A
    Radiat Res; 1990 Jan; 121(1):14-20. PubMed ID: 2300664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 227Th-EDTMP: a potential therapeutic agent for bone metastasis.
    Washiyama K; Amano R; Sasaki J; Kinuya S; Tonami N; Shiokawa Y; Mitsugashira T
    Nucl Med Biol; 2004 Oct; 31(7):901-8. PubMed ID: 15464392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents.
    Henriksen G; Bruland OS; Larsen RH
    Anticancer Res; 2004; 24(1):101-5. PubMed ID: 15015582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: an in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the alpha-emitter 227Th.
    Melhus KB; Larsen RH; Stokke T; Kaalhus O; Selbo PK; Dahle J
    Cancer Biother Radiopharm; 2007 Aug; 22(4):469-79. PubMed ID: 17803441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Chemical Society--227th Annual Meeting. Antibacterials and anti-inflammatories. 28 March - 1 April 2004, Anaheim, CA, USA.
    Garvey R; Veryard C
    IDrugs; 2004 May; 7(5):420-2. PubMed ID: 15154097
    [No Abstract]   [Full Text] [Related]  

  • 8. [The Proceedings of the 227th Kanto-Koshinetsu Regional Meeting of the Japanese Society of Neurology].
    Rinsho Shinkeigaku; 2019; 59(4):215-228. PubMed ID: 31019182
    [No Abstract]   [Full Text] [Related]  

  • 9. Level structure and reflection asymmetry in 227Th.
    Liang CF; Paris P; Sheline RK; Nosek D; Kvasil J
    Phys Rev C Nucl Phys; 1995 Mar; 51(3):1199-1210. PubMed ID: 9970169
    [No Abstract]   [Full Text] [Related]  

  • 10. Late effects after incorporation of the short-lived alpha-emitters 224Ra and 227Th in mice.
    Müller WA; Gössner W; Hug O; Luz A
    Health Phys; 1978 Jul; 35(1):33-55. PubMed ID: 102611
    [No Abstract]   [Full Text] [Related]  

  • 11. American Chemical Society--227th annual meeting. Diabetes. 28 March - 1 April 2004, Anaheim, CA, USA.
    Rotella DP
    IDrugs; 2004 May; 7(5):428-9. PubMed ID: 15154100
    [No Abstract]   [Full Text] [Related]  

  • 12. Further reports on the relation between Arakawa's reaction and thiamine content of human milk. Part 2. Bound thiamine of human milk; 227th report of the peroxidase reaction.
    NAITO T
    Tohoku J Exp Med; 1952 Jun; 56(1-2):23-9. PubMed ID: 13005481
    [No Abstract]   [Full Text] [Related]  

  • 13. American Chemical Society--227th Annual Meeting. NMDA receptor. 28 March - 1 April 2004, Anaheim, CA, USA.
    Rotella DP
    IDrugs; 2004 May; 7(5):433-5. PubMed ID: 15154102
    [No Abstract]   [Full Text] [Related]  

  • 14. American Chemical Society--227th annual meeting. Highlights. 28 March - 1 April 2004, Anaheim, CA, USA.
    Garvey R; Veryard C
    IDrugs; 2004 May; 7(5):426-7. PubMed ID: 15154099
    [No Abstract]   [Full Text] [Related]  

  • 15. American Chemical Society--227th Annual Meeting. New disclosures. 28 March - 1 April 2004, Anaheim, CA, USA.
    Garvey R; Veryard C
    IDrugs; 2004 May; 7(5):423-5. PubMed ID: 15154098
    [No Abstract]   [Full Text] [Related]  

  • 16. American Chemical Society--227th annual meeting. Neuroprotection. 28 March - 1 April 2004, Anaheim, CA, USA.
    Rotella DP
    IDrugs; 2004 May; 7(5):430-2. PubMed ID: 15154101
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeted α-therapy using 227Th-APOMAB and cross-fire antitumour effects: preliminary in-vivo evaluation.
    Staudacher AH; Bezak E; Borysenko A; Brown MP
    Nucl Med Commun; 2014 Dec; 35(12):1284-90. PubMed ID: 25192189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab.
    Heyerdahl H; Krogh C; Borrebæk J; Larsen Å; Dahle J
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):563-70. PubMed ID: 21195878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superallowed α Decay to Doubly Magic ^{100}Sn.
    Auranen K; Seweryniak D; Albers M; Ayangeakaa AD; Bottoni S; Carpenter MP; Chiara CJ; Copp P; David HM; Doherty DT; Harker J; Hoffman CR; Janssens RVF; Khoo TL; Kuvin SA; Lauritsen T; Lotay G; Rogers AM; Sethi J; Scholey C; Talwar R; Walters WB; Woods PJ; Zhu S
    Phys Rev Lett; 2018 Nov; 121(18):182501. PubMed ID: 30444390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of separation technology for the removal of radium-223 from decayed thorium-227 in drug formulations. Material screening and method development.
    Frenvik JO; Kristensen S; Ryan OB
    Drug Dev Ind Pharm; 2016 Aug; 42(8):1215-24. PubMed ID: 26569601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.